



National
Comprehensive
Cancer
Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Thymomas and Thymic Carcinomas

Version 1.2015

NCCN.org

Continue



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2015 Panel Members

Thymomas and Thymic Carcinomas

[NCCN Guidelines Index](#)
[Thymic Table of Contents](#)
[Discussion](#)

* David S. Ettinger, MD/Chair †
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Douglas E. Wood, MD/Vice-Chair ¶
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance

* Gregory J. Riely, MD, PhD/Lead †
Memorial Sloan Kettering Cancer Center

Wallace Akerley, MD †
Huntsman Cancer Institute
at the University of Utah

Lyudmila A. Bazhenova, MD † ‡
UC San Diego Moores Cancer Center

Hossein Borghaei, DO, MS † ‡
Fox Chase Cancer Center

David Ross Camidge, MD, PhD †
University of Colorado Cancer Center

Richard T. Cheney, MD ≠
Roswell Park Cancer Institute

Lucian R. Chirieac, MD ≠
Dana-Farber/Brigham and Women's
Cancer Center

Thomas A. D'Amico, MD ¶
Duke Cancer Institute

Todd L. Demmy, MD ¶
Roswell Park Cancer Institute

Thomas Dilling, MD §
Moffitt Cancer Center

Ramaswamy Govindan, MD †
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Frederic W. Grannis, Jr., MD ¶
City of Hope Comprehensive Cancer Center

Leora Horn, MD, MSc †
Vanderbilt-Ingram Cancer Center

Thierry M. Jahan, MD † ‡
UCSF Helen Diller Family
Comprehensive Cancer Center

Ritsuko Komaki, MD §
The University of Texas
MD Anderson Cancer Center

Mark G. Kris, MD †
Memorial Sloan Kettering Cancer Center

Lee M. Krug, MD †
Memorial Sloan Kettering Cancer Center

Rudy P. Lackner, MD ¶
Fred & Pamela Buffett Cancer Center

Michael Lanuti, MD ¶
Massachusetts General Hospital Cancer Center

Rogério Lilenbaum, MD †
Yale Cancer Center/Smilow Cancer Hospital

Jules Lin, MD ¶
University of Michigan
Comprehensive Cancer Center

Billy W. Loo, Jr., MD, PhD §
Stanford Cancer Institute

Renato Martins, MD, MPH †
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Gregory A. Otterson, MD †
The Ohio State University Comprehensive
Cancer Center - James Cancer Hospital
and Solove Research Institute

Jyoti D. Patel, MD ‡
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Katherine M. Pisters, MD †
The University of Texas
MD Anderson Cancer Center

Karen Reckamp, MD, MS † ‡
City of Hope Comprehensive Cancer Center

Eric Rohren, MD, PhD ϕ
The University of Texas
MD Anderson Cancer Center

Steven E. Schild, MD §
Mayo Clinic Cancer Center

Theresa A. Shapiro, MD, PhD ≠
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Scott J. Swanson, MD ¶
Dana-Farber/Brigham and Women's
Cancer Center

Kurt Tauer, MD †
University of Tennessee Health Science Center

Stephen C. Yang, MD ¶
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

NCCN

Fay Ferkle, PharmD
Kristina Gregory, RN, MSN, OCN
Miranda Hughes, PhD

† Medical oncology
¶ Surgery/Surgical oncology
§ Radiation oncology/Radiotherapy
≠ Pathology
‡ Hematology/Hematology oncology
ϕ Diagnostic/Interventional radiology
≠ Patient advocate
*Writing committee member

Continue

[NCCN Guidelines Panel Disclosures](#)



National
Comprehensive
Cancer
Network®

NCCN Guidelines Version 1.2015 Table of Contents

Thymomas and Thymic Carcinomas

[NCCN Guidelines Index](#)
[Thymic Table of Contents](#)
[Discussion](#)

[NCCN Thymomas and Thymic Carcinomas Panel Members](#)

[Summary of Guidelines Updates](#)

[Initial Evaluation \(THYM-1\)](#)

[Initial Management \(THYM-2\)](#)

[Postoperative Treatment and Management \(THYM-3\)](#)

[Locally Advanced, Advanced, or Recurrent Disease \(THYM-4\)](#)

[Principles of Surgical Resection \(THYM-A\)](#)

[Principles of Radiation Therapy \(THYM-B\)](#)

[Principles of Chemotherapy for Thymic Malignancies \(THYM-C\)](#)

[World Health Organization Histologic Classification \(THYM-D\)](#)

[Staging \(ST-1\)](#)

Clinical Trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, [click here: nccn.org/clinical_trials/physician.html](#).

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise specified.

See [NCCN Categories of Evidence and Consensus](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2015.



NCCN Guidelines Version 1.2015 Updates

Thymomas and Thymic Carcinomas

Updates in Version 1.2015 of the NCCN Guidelines for Thymomas and Thymic Carcinomas from Version 1.2014 include:

[THYM-1](#)

- Footnote “a” added: “Well-defined anterior mediastinal mass in the thymic bed, tumor markers negative, absence of other adenopathy, and absence of continuity with the thyroid.” (also applies to THYM-2)

[THYM-2](#)

- Footnote “b” modified: “Determination of resectability should be made by a board-certified thoracic surgeon, *with primary focus on thoracic oncology.*”
- Locally advanced, unresectable modified: “Biopsy should not violate the pleural space changed to *Avoid transpleural approach.*”

[THYM-3](#)

- Column heading changed from “Resectable Disease” to “Postoperative Management.”
- R1 resection, thymic carcinoma: Postoperative RT changed from “+ chemotherapy” to “± chemotherapy.”
- R2 resection: RT clarified as *Definitive* RT.

[THYM-4](#)

- “Isolated solitary metastasis” changed to “Solitary metastasis *or ipsilateral pleural metastasis.*”
- “Evidence of distant metastases” changed to “Evidence of *extrathoracic* metastases.”

[THYM-A](#)

- Bullet 7 modified: “During thymectomy, the pleural surfaces should be examined for pleural metastases. ~~In some cases~~ *If feasible*, resection of pleural metastases to achieve complete gross resection ~~may be~~ *is appropriate.*”
- References 2–5 added.

[THYM-B 1 of 2](#)

- General Principles, bullet 2 was modified: “*Definitive RT* should be given for patients with unresectable disease (if disease progresses on induction chemotherapy), incompletely resected invasive thymoma or thymic carcinoma, *or as adjuvant therapy after chemotherapy and surgery for patients with locally advanced disease.*”

[THYM-B 2 of 2](#)

- Radiation Techniques, bullet 4 modified: “In addition to following the normal tissue constraints recommendation using the Principles of RT for non-small cell lung cancer, more conservative limits are recommended to minimize the dose volumes to all the normal structures. Since these patients are younger and mostly long-term survivors, the *mean* dose to the total heart should be ~~limited to ≤30 Gy~~ *as low as reasonably achievable.*”

[THYM-C 1 of 2](#)

- Sunitinib (Thymic carcinomas only) and everolimus added as treatment options in second-line chemotherapy with category 2A designations.


[THYM-C 2 of 2](#)

- References 7 and 9 added for sunitinib and everolimus. Reference 13 replaced.

[THYM-D](#)

- World Health Organization Histologic Classification moved from previous page ST-2.

INITIAL EVALUATION



^aWell-defined anterior mediastinal mass in the thymic bed, tumor markers negative, absence of other adenopathy, and absence of continuity with the thyroid.


Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

INITIAL MANAGEMENT



^aWell-defined anterior mediastinal mass in the thymic bed, tumor markers negative, absence of other adenopathy, and absence of continuity with the thyroid.

^bDetermination of resectability should be made by a board-certified thoracic surgeon, with primary focus on thoracic oncology.

^cSee [Principles of Surgical Resection \(THYM-A\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

POSTOPERATIVE TREATMENT^c

POSTOPERATIVE MANAGEMENT



^cSee Principles of Surgical Resection (THYM-A).

^dR0 = no residual tumor, R1 = microscopic residual tumor, R2 = macroscopic residual tumor.

^eSee Principles of Radiation Therapy (THYM-B).

^fSee Principles of Chemotherapy for Thymic Malignancies (THYM-C).

^gThe duration for surveillance has not been established.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.




NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

**LOCALLY ADVANCED, ADVANCED,
OR RECURRENT DISEASE**

TREATMENT



^bDetermination of resectability should be made by a board-certified thoracic surgeon, with primary focus on thoracic oncology.

^c[See Principles of Surgical Resection \(THYM-A\).](#)

^e[See Principles of Radiation Therapy \(THYM-B\).](#)

^f[See Principles of Chemotherapy for Thymic Malignancies \(THYM-C\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

PRINCIPLES OF SURGICAL RESECTION

- **Surgical resection should be performed on carefully evaluated patients by board-certified thoracic surgeons. Locally advanced (unresectable) and resectable stage \geq II cases should be discussed and evaluated by a multidisciplinary team.**
- **Surgical biopsy should be avoided if a resectable thymoma is strongly suspected based on clinical and radiologic features.**
- **Biopsy of a possible thymoma should avoid a transpleural approach.**
- **Prior to surgery, patients should be evaluated for signs and symptoms of myasthenia gravis and should be medically controlled prior to undergoing surgical resection.**
- **Goal of surgery is complete excision of the lesion with total thymectomy and complete resection of contiguous and noncontiguous disease.**
- **Complete resection may require the resection of adjacent structures, including the pericardium, phrenic nerve, pleura, lung, and even major vascular structures. Bilateral phrenic nerve resection should be avoided due to severe respiratory morbidity.**
- **During thymectomy, the pleural surfaces should be examined for pleural metastases. If feasible, resection of pleural metastases to achieve complete gross resection is appropriate.**
- **Minimally invasive procedures are not routinely recommended due to the lack of long-term data. However, minimally invasive procedures may be considered if all oncologic goals can be met as in standard procedures, and if performed in specialized centers by surgeons with experience in these techniques.¹⁻⁵**

¹Pennathur A, Qureshi I, Schubert MJ, et al. Comparison of surgical techniques for early stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. *J Thorac Cardiovasc Surg* 2011;141:694-701.

²Ye B, Tantai JC, Ge XX, et al. Surgical techniques for early-stage thymoma: video-assisted thorascopic thymectomy versus transsternal thymectomy. *J Thorac Cardiovasc Surg* 2014;147:1599-1603.

³Sakamaki Y, Oda T, Kanazawa G, et al. Intermediate-term oncologic outcomes after video-assisted thorascopic thymectomy for early-stage thymoma. *J Thorac Cardiovasc Surg* 2014;148:1230-1237.

⁴Manoly I, Whistance RN, Sreekumar R, et al. Early and mid-term outcomes of trans-sternal and video-assisted thorascopic surgery for thymoma. *Eur J Cardiothorac Surg* 2014;45:e187-193.

⁵Liu TJ, Lin MW, Hsieh MS, et al. Video-assisted thorascopic surgical thymectomy to treat early thymoma: a comparison with the conventional transsternal approach. *Ann Surg Oncol* 2014;322-328.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

PRINCIPLES OF RADIATION THERAPY (1 of 2)^{1,2}

General Principles

- Recommendations regarding RT should be made by a board-certified radiation oncologist.
- Definitive RT should be given for patients with unresectable disease (if disease progresses on induction chemotherapy), incompletely resected invasive thymoma or thymic carcinoma, or as adjuvant therapy after chemotherapy and surgery for patients with locally advanced disease.
- Radiation oncologists need to communicate with the surgeon to review the operative findings and to help determine the target volume at risk. They also need to communicate with the pathologist regarding the detailed pathology on histology, disease extent such as extracapsular extension, and surgical margins.
- Acronyms and abbreviations for RT are the same as listed in the Principles of RT for non-small cell lung cancer. [See NCCN Guidelines for Non-Small Cell Lung Cancer.](#)

Radiation Dose

- The dose and fractionation schemes of RT depend on the indication of the radiation and the completeness of surgical resection in postoperative cases.
- A dose of 60 to 70 Gy should be given to patients with unresectable disease.
- For adjuvant treatment, the radiation dose consists of 45 to 50 Gy for clear/close margins and 54 Gy for microscopically positive resection margins. A total dose of 60 Gy and above should be given to patients with gross residual disease (similar to patients with unresectable disease),^{3,4} when conventional fractionation (1.8–2.0 Gy per daily fraction) is applied.

[See Radiation Volume and Radiation Techniques \(THYM-B 2 of 2\)](#)

¹Gomez D, Komaki R, Yu J, et al. Radiation therapy definitions and reporting guidelines for thymic malignancies. J Thorac Oncol 2011;6:S1743-1748.

²Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. J Thorac Oncol 2010;5:S336-343.

³Mornex F, Resbeut M, Richaud P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. Int J Radiat Oncol Biol Phys 1995;32:651-659.

⁴Myojin M, Choi NC, Wright CD, et al. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. Int J Radiat Oncol Biol Phys. 2000;46(4):927-933.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

PRINCIPLES OF RADIATION THERAPY (2 of 2)

Radiation Volume

- The gross tumor volume should include any grossly visible tumor. Surgical clips indicative of gross residual tumor should be included for postoperative adjuvant RT.
- The clinical target volume (CTV) for postoperative RT should encompass the entire thymus (for partial resection cases), surgical clips, and any potential sites with residual disease. The CTV should be reviewed with the thoracic surgeon.
- Extensive elective nodal irradiation (entire mediastinum and bilateral supraclavicular nodal regions) is not recommended, as thymomas do not commonly metastasize to regional lymph nodes.⁵
- The planning target volume (PTV) should consider the target motion and daily setup error. The PTV margin should be based on the individual patient's motion, simulation techniques used (with and without inclusion motion), and reproducibility of daily setup of each clinic.

Radiation Techniques

- CT-based planning is highly recommended. CT scans should be taken in the treatment position with arms raised above the head (treatment position). Simulations of target motion are encouraged whenever possible. CT scans can be performed at the end of natural inhale, exhale, and under free breathing when more sophisticated techniques like 4-D CT, gated CT, or active breathing control are not available. Target motion should be managed using the Principles of RT for non-small cell lung cancer. [See NCCN Guidelines for Non-Small Cell Lung Cancer](#). Intravenous contrast is beneficial in the unresectable setting.
- Radiation beam arrangements should be selected based on the shape of PTV aiming to confine the prescribed high dose to the target and minimize dose to adjacent critical structures. Anterior-posterior and posterior-anterior ports weighting more anteriorly, or wedge pair technique may be considered. These techniques, although commonly used during the traditional 2-D era, can generate an excessive dose to normal tissue. A dose-volume histogram of the lungs, heart, and cord need to be carefully reviewed for each plan.
- RT should be given by 3-D conformal technique to reduce surrounding normal tissue damage (eg, heart, lungs, esophagus, spinal cord). Intensity-modulated RT (IMRT) may further improve the dose distribution and decrease the dose to the normal tissue as indicated. If IMRT is applied, the ASTRO/ACR IMRT guidelines should be strictly followed.^{6,7}
- In addition to following the normal tissue constraints recommendation using the Principles of RT for non-small cell lung cancer, more conservative limits are recommended to minimize the dose volumes to all the normal structures. Since these patients are younger and mostly long-term survivors, the mean dose to the total heart should be as low as reasonably achievable.

[See General Principles and Radiation Dose \(THYM-B 1 of 2\)](#)

⁵Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc Surg 1997;113:55-63.

⁶Moran JM, Dempsey M, Eisbruch A, et al. Safety considerations for IMRT: executive summary. Med Phys. 2011;38:5067-5072.

⁷Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). Int J Radiat Oncol Biol Phys 2009;73:9-14.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

PRINCIPLES OF CHEMOTHERAPY FOR THYMIC MALIGNANCIES

FIRST-LINE COMBINATION CHEMOTHERAPY REGIMENS

CAP¹ (preferred for thymoma)

Cisplatin 50 mg/m² IV day 1
Doxorubicin 50 mg/m² IV day 1
Cyclophosphamide 500 mg/m² IV day 1
Administered every 3 weeks

CAP with Prednisone²

Cisplatin 30 mg/m² days 1–3
Doxorubicin, 20 mg/m²/d
IV continuous infusion on days 1–3
Cyclophosphamide 500 mg/m² IV on day 1
Prednisone 100 mg/day days 1–5
Administered every 3 weeks

ADOC³

Cisplatin 50 mg/m² IV day 1
Doxorubicin 40 mg/m² IV day 1
Vincristine 0.6 mg/m² IV day 3
Cyclophosphamide 700 mg/m² IV day 4
Administered every 3 weeks

PE⁴

Cisplatin 60 mg/m² IV day 1
Etoposide 120 mg/m²/d IV days 1–3
Administered every 3 weeks

VIP⁵

Etoposide 75 mg/m² on days 1–4
Ifosfamide 1.2 g/m² on days 1–4
Cisplatin 20 mg/m² on days 1–4
Administered every 3 weeks

Carboplatin/Paclitaxel⁶ (preferred for thymic carcinoma)

Carboplatin AUC 6
Paclitaxel 225 mg/m²
Administered every 3 weeks

SECOND-LINE CHEMOTHERAPY

Sunitinib (Thymic carcinomas only)⁷

Pemetrexed⁸
Everolimus⁹
Paclitaxel¹⁰⁻¹¹
Octreotide (including LAR) +/- prednisone¹²
Gemcitabine¹³
5-FU and leucovorin¹⁴⁻¹⁵
Etoposide⁴
Ifosfamide¹⁶

[References on THYM-C 2 of 2](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015

Thymomas and Thymic Carcinomas

PRINCIPLES OF CHEMOTHERAPY FOR THYMIC MALIGNANCIES

REFERENCES

- ¹Loehrer PJ Sr, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. *J Clin Oncol* 1994;12:1164–1168.
- ²Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. *Lung Cancer* 2004;44:369–379.
- ³Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. *Cancer* 1991;68:30–33.
- ⁴Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *J Clin Oncol* 1996;14:814–820.
- ⁵Loehrer PJ Sr, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. *Cancer* 2001;91:2010–2015.
- ⁶Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. *J Clin Oncol* 2011;29:2060–2065.
- ⁷Thomas A, Rajan A, Berman AW, et al. Phase II trial of sunitinib in patients with thymic epithelial tumors (TET) [abstract]. *J Clin Oncol* 2014;32(suppl 5): Abstract 7525.
- ⁸Loehrer PJ, Yiannoutsos CT, Dropcho S, et al. A phase II trial of pemetrexed in patients with recurrent thymoma or thymic carcinoma [abstract]. *J Clin Oncol* 2006;24(Suppl 18):Abstract 7079.
- ⁹Zucali PA, De Pas TM, Palmieri G, et al. Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy [abstract]. *J Clin Oncol* 2014;32(suppl 5): Abstract 7527.
- ¹⁰Umemura S, Segawa Y, Fujiwara K, et al. A case of recurrent metastatic thymoma showing a marked response to paclitaxel monotherapy. *Jpn J Clin Oncol* 2002;32:262–265.
- ¹¹Yamamoto N, Tsurutani J, Yoshimura N, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. *Anticancer Res* 2006;26:777–781.
- ¹²Loehrer PJ Sr, Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. *J Clin Oncol* 2004;22:293–299.
- ¹³Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). *Ann Oncol* 2010;21:1168-1172.
- ¹⁴Stewart DJ, Dahrouge S, Soltys KM, Evans WK. A phase II study of 5-fluorouracil plus high-dose folinic acid in the treatment of recurrent small cell lung cancer. *Am J Clin Oncol* 1995;18:130–132.
- ¹⁵André T, Louvet C, Maindault-Goebel F, et al. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. *GERCOR. Eur J Cancer* 1999;35:1343–1347.
- ¹⁶Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. *J Clin Oncol* 1999;17:2737–2744.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

NCCN Guidelines Version 1.2015
Thymomas and Thymic Carcinomas**World Health Organization Histologic Classification¹**

<u>Type</u>	<u>Description</u>
A	A tumor composed of a population of neoplastic thymic epithelial cells having spindle/oval shape, lacking nuclear atypia, and accompanied by few or no nonneoplastic lymphocytes.
AB	A tumor in which foci having the features of type A thymoma are admixed with foci rich in lymphocytes.
B1	A tumor that resembles the normal functional thymus in that it combines large expanses having an appearance practically indistinguishable from normal thymic cortex with areas resembling thymic medulla.
B2	A tumor in which the neoplastic epithelial component appears as scattered plump cells with vesicular nuclei and distinct nucleoli among a heavy population of lymphocytes. Perivascular spaces are common and sometimes very prominent. A perivascular arrangement of tumor cells resulting in a palisading effect may be seen.
B3	A type of thymoma predominantly composed of epithelial cells having a round or polygonal shape and exhibiting no or mild atypia. They are admixed with a mild component of lymphocytes, resulting in a sheetlike growth of the neoplastic epithelial cells.
C	A thymic tumor (thymic carcinoma) exhibiting clear-cut cytologic atypia and a set of cytoarchitectural features no longer specific to the thymus, but rather analogous to those seen in carcinomas of other organs. Type C thymomas lack immature lymphocytes; whatever lymphocytes may be present are mature and usually admixed with plasma cells.

¹Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. *Ann Thorac Surg* 2004;77:1183-1188.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015 Staging Thymomas and Thymic Carcinomas

Staging

Table 1. Modified Masaoka clinical staging of thymoma^{1,2}

<u>Masaoka stage</u>	<u>Diagnostic criteria</u>
Stage I	Macroscopically and microscopically completely encapsulated
Stage II	(A) Microscopic transcapsular invasion (B) Macroscopic invasion into surrounding fatty tissue or grossly adherent to but not through mediastinal pleura or pericardium
Stage III	Macroscopic invasion into neighboring organs (ie, pericardium, great vessels, lung) (A) Without invasion of great vessels (B) With invasion of great vessels
Stage IV	(A) Pleural or pericardial dissemination (B) Lymphogenous or hematogenous metastasis

Table 2. TNM Classification³

<u>T</u>	<u>Primary Tumor</u>
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
T1	Tumor completely encapsulated
T2	Tumor invades pericapsular connective tissue
T3	Tumor invades into neighboring structures, such as pericardium, mediastinal pleura, thoracic wall, great vessels and lung
T4	Tumor with pleural or pericardial dissemination
<u>N</u>	<u>Regional Lymph Nodes</u>
NX	Regional lymph nodes cannot be assessed
N0	No regional lymph node metastasis
N1	Metastasis in anterior mediastinal lymph nodes
N2	Metastasis in other intrathoracic lymph nodes excluding anterior mediastinal lymph nodes
N3	Metastasis in scalene and/or supraclavicular lymph nodes
<u>M</u>	<u>Distant Metastasis</u>
MX	Distant metastasis cannot be assessed
M0	No distant metastasis
M1	Distant metastasis

Stage Grouping

Stage I	T1	N0	M0
Stage II	T2	N0	M0
Stage III	T1	N1	M0
	T2	N1	M0
	T3	N0, 1	M0
Stage IV	T4	Any N	M0
	Any T	N2, 3	M0
	Any T	Any N	M1

¹Reprinted from Crit Rev Oncol Hematol, 65, Wright CD, Management of thymomas, 109-120, Copyright (2008), with permission from Elsevier.

²Note that the Masaoka staging system is also used to stage thymic carcinomas.

³Travis WD, Brambilla E, Müller-Hermelink HK, Harris, CC. World Health Organization Classification of Tumours of the Lung Pleura, Thymus and Heart. IARC, Lyon, 2004.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 1.2015 Thymomas and Thymic Carcinomas

Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 08/13/13

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.


Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview.....	MS-2
Mediastinal Masses	MS-2
Thymic Masses.....	MS-3
Thymomas	MS-3
Thymic Carcinomas.....	MS-5
References	MS-6



Overview

Thymomas are a common primary tumor in the anterior mediastinum, although they are rare (1.5 cases/million).¹⁻³ Thymic carcinomas are very rare. Thymomas and thymic carcinomas originate in the thymus. Although thymomas can spread locally, they are much less invasive than thymic carcinomas.¹ Patients with thymomas have 5-year survival rates of approximately 78%.⁴ However, 5-year survival rates for thymic carcinomas are only approximately 40%.^{5,6} The NCCN Guidelines for Thymomas and Thymic Carcinomas outline the evaluation, treatment, and management of these mediastinal tumors; the *Updates* describe the most recent revisions. These NCCN Guidelines were first published in 2010.

Mediastinal Masses

Masses in the anterior mediastinum can be neoplasms (ie, thymomas, lymphomas, thymic carcinomas, thymic carcinoids, thymolipomas, germ cell tumors, lung metastases) or non-neoplastic conditions (ie, intrathoracic goiter, thymic cysts, lymphangiomas, aortic aneurysms).^{2,7,8} Many mediastinal masses are benign, especially those occurring in asymptomatic patients; however, symptomatic patients often have malignant mediastinal lesions. All patients with a mediastinal mass should be evaluated to determine the type of mass and to determine the extent of disease before treatment. It is essential to differentiate between thymic malignancies and other conditions (eg, lung metastases, lymphoma, goiter, germ cell tumors) before treatment, because management differs for these conditions.^{9,10} Most masses in the mediastinum are metastases from a primary lung cancer (eg, non-small cell lung cancer). However, about 50% of primary cancers in the anterior mediastinum are thymomas.¹¹

Patients with thymomas often have an indolent presentation, whereas those with lymphoma or germ cell tumors have a rapid onset of symptoms.¹⁰ Lymphomas typically manifest as generalized disease but can also be primary anterior mediastinal lesions (ie, nodular sclerosing Hodgkin's disease, non-Hodgkin's lymphomas [diffuse large B-cell lymphoma and acute lymphoblastic lymphoma]); patients typically have lymphadenopathy (see the NCCN Guidelines for Non-Hodgkin's Lymphomas and Hodgkin Lymphoma).^{8,12} Thymic carcinoids are rare tumors that are discussed in the NCCN Guidelines for Neuroendocrine Tumors; they are associated with multiple endocrine neoplasia type 1 (MEN1) syndrome.^{13,14} Lung carcinoids are discussed in the NCCN Guidelines for Small Cell Lung Cancer (see *Lung Neuroendocrine Tumors*). Extragonadal germ cell tumors are rare tumors that occur in teenagers and young adults.

Recommended tests for assessing mediastinal masses include chest CT with contrast and blood chemistry studies.¹⁵⁻¹⁹ On CT, a thymoma is usually a well-defined round or oval mass in the thymus.^{17,20} Recently, low-dose CT was found to be useful for detecting lung cancer in high-risk individuals (see the NCCN Guidelines for Lung Cancer Screening).²¹ Mediastinal masses (eg, lung metastases, thymomas, thymic carcinomas) may be detected in individuals undergoing lung cancer screening.

In patients who cannot tolerate iodinated contrast, MRI of the chest may be useful.¹⁷ Combined PET-CT may be useful for determining whether distant metastases are present.²² PET-CT provides better correlation with anatomic structures than PET alone. Alpha-fetoprotein (AFP) levels and beta-human chorionic gonadotropin (beta-hCG) levels may be measured to rule out germ cell tumors.

Thymic Masses

All patients with thymic malignancies should be evaluated by radiation oncologists, surgeons, medical oncologists, diagnostic imaging specialists, and pulmonologists to determine the optimal plan of care before treatment.²³ It is critical to determine whether the mass can be surgically resected; a board-certified thoracic surgeon should make this decision. Total thymectomy and complete surgical excision of the tumor are the gold standard of treatment and are recommended whenever possible for most resectable tumors.^{4,5,10,24,25} During thymectomy, the pleural surfaces should be examined for metastases. To achieve a complete gross resection, removal of pleural metastases may be appropriate in some patients.²⁶⁻²⁸ Core-needle or open biopsy is recommended for locally advanced, unresectable thymic masses.⁷ Minimally invasive procedures are not typically recommended, because long-term data are not available regarding recurrence and survival. However, minimally invasive procedures may be considered if standard oncologic goals can be met (as previously described) and if performed in specialized centers with surgeons with expertise in these techniques.²⁹⁻³⁴

Although several staging systems exist, the Masaoka staging system is the most widely accepted system for management and determination of prognosis for both thymomas and thymic carcinomas.^{4,5,35-41} The International Thymic Malignancy Interest Group (ITMIG) suggests using the Masaoka-Koga stage classification.^{35,42} The TNM staging system is less commonly used.⁴³ Patients with stage I to III thymomas have a 5-year survival rate of approximately 85% versus 65% for stage IV disease.^{4,44,45} In approximately 50% of patients, mortality is not related to thymoma.³⁶ In approximately 20% of patients, mortality is related to myasthenia gravis.

The WHO histologic classification system can be used to distinguish between thymomas, thymic carcinomas, and thymic carcinoids.^{43,46} The WHO classification is also used to differentiate among different histologic types of thymomas (ie, A, AB, B1, B2, B3); however, it is difficult to classify thymomas.⁴⁷ Thymic carcinomas are type C in the WHO classification, although they are very different from thymomas and are not advanced thymomas.⁴⁸ However, the histologic subtype is less important for management than the extent of resection (ie, R0, R1, R2).^{5,49-52} For stage III to IV thymomas, 5-year survival rates have been reported to be 90% in patients with total resection.⁵ For thymic carcinomas, 5-year survival rates are lower, even in those with total resection.⁵³

Thymomas

Thymomas typically occur in adults 40 to 70 years of age; they are rare in children or adolescents.¹⁰ Although some patients are asymptomatic, others present with chest pain, cough, or dyspnea. Approximately 30% to 50% of patients with thymomas have myasthenia gravis; therefore, patients should be evaluated for myasthenia gravis (eg, by history and/or measuring serum antiacetylcholine receptor antibody levels).⁴⁴ Although thymomas can be locally invasive (eg, pleura, lung), they uncommonly spread to regional lymph nodes or distant sites.^{4,44} Surgery (ie, total thymectomy and complete excision of tumor) is recommended for all resectable thymomas for patients who can tolerate the surgery.^{11,54} For resected stage I and II thymomas, the 10-year survival rate is excellent (approximately 90% and 70%, respectively).^{10,55} Completeness of resection is the most important predictor of outcome. Surgical biopsy is not necessary if a resectable thymoma is strongly suspected based on clinical and radiologic features (eg, patients have myasthenia gravis and a characteristic mass on CT).¹⁰ A transpleural approach should be avoided during biopsy of a possible thymoma.^{56,57}

Small biopsy sampling (fine-needle or core-needle biopsy) does not always indicate whether invasion is present.⁵⁸ The ITMIG has established procedures for reporting the surgical and pathologic findings from resection specimens.⁵⁹

Before any surgical procedure, all patients suspected of having thymomas (even those without symptoms) should have their serum antiacetylcholine receptor antibody levels measured to determine whether they have myasthenia gravis to avoid respiratory failure during surgery. Symptoms suggestive of myasthenia gravis include drooping eyelids, double vision, drooling, difficulty climbing stairs, hoarseness, and/or dyspnea. If patients have myasthenia gravis, they should receive treatment by a neurologist with experience in myasthenia gravis before undergoing surgical resection.^{56,60-62}

Adjuvant therapy is not recommended for completely resected (R0) stage I thymomas or for stage I thymic carcinomas.^{24,63,64} For incompletely resected thymomas, postoperative radiation therapy (RT) is recommended.^{24,65} Note that extensive elective nodal radiation is not recommended, because thymomas do not typically metastasize to regional lymph nodes.^{4,66} CT-based treatment planning is highly recommended before RT.⁶⁷ RT should be given by the 3-D conformal technique to reduce damage to surrounding normal tissue (eg, heart, lungs, esophagus, spinal cord).

Use of intensity-modulated RT (IMRT) may decrease the dose to the normal tissues.^{67,68} However, if IMRT is used, guidelines from the ATC/NCI and ASTRO/ACR should be followed.⁶⁹⁻⁷² The ICRU-83 (International Commission on Radiation Units and Measurements Report 83) recommendations are also a useful resource.^{71,73} Although the normal tissue constraints recommendations for lung cancer may be used (see the *Principles of Radiation Therapy* in the NCCN Guidelines

for Non-Small Cell Lung Cancer), more conservative limits are recommended to minimize the dose volumes to all the normal structures.^{74,75} Because these patients are younger and usually long-term survivors, the total dose to the heart should be limited to 30 Gy or less.

A definitive total dose of 60 to 70 Gy is recommended for patients with unresectable disease. For adjuvant treatment, a total dose of 45 to 50 Gy is recommended for clear or close margins; a total dose of 54 Gy is recommended for microscopically positive resection margins.^{67,68}

However, a total dose of 60 Gy or more (1.8–2 Gy/fraction per day) is recommended for patients with gross residual disease after surgery.^{76,77}

Postoperative RT can be considered in patients with thymomas and thymic carcinomas who have capsular invasion after an R0 resection, although this is a category 2B recommendation.^{64,67,78-80} Patients with stage III (with macroscopic invasion into neighboring organs) thymoma or those with thymic carcinoma have higher risks of recurrent disease and, as such, postoperative radiation is recommended to maximize local control.^{81,82} Increasing evidence suggests that patients with stage II thymoma may not benefit from postoperative radiation.^{24,63,64,79} Postoperative chemotherapy is also not beneficial.⁸³

For advanced disease, chemotherapy with (or without) RT is recommended.^{64,84-96} Although 6 different combination regimens are provided in the NCCN algorithm, cisplatin/doxorubicin-based regimens seem to yield the best outcomes; the panel feels that cisplatin/doxorubicin/cyclophosphamide is the regimen of choice for thymoma.^{24,97,98} However, non-anthracycline regimens (eg, cisplatin/etoposide [with or without ifosfamide], carboplatin/paclitaxel) may be useful for patients who cannot tolerate the more aggressive regimens.^{98,99} For thymic carcinoma, the panel recommends

carboplatin/paclitaxel.^{99,100} Induction therapy followed by surgery may be useful for thymic malignancies initially considered unresectable.^{53,92,101,102}

Second-line systemic therapy includes etoposide, ifosfamide, pemetrexed, octreotide (long-acting release [LAR]; with or without prednisone), 5-FU, gemcitabine, and paclitaxel.^{84,85,98,103-106} However, none of these agents have been assessed in randomized trials. Octreotide may be useful in patients with thymoma who have a positive octreotide scan or symptoms of carcinoid syndrome. After resection, panel members agree that surveillance for recurrence should include chest CT every 6 months for 2 years, then annually for 10 years for thymoma and 5 years for thymic carcinoma.¹⁷ Given the risk of later recurrence for thymoma, surveillance should continue for at least 10 years. However, the duration for surveillance for thymomas and thymic carcinomas has not been established in published studies. Patients with thymoma also have an increased risk for second malignancies, although no particular screening studies are recommended.¹⁰⁷

Thymic Carcinomas

Thymic carcinomas are rare aggressive tumors that often metastasize to regional lymph nodes and distant sites; thus, they have a worse prognosis than thymomas (5-year survival rates, 30%–50%).^{2,5,6,8,51,52,108,109} These tumors can be distinguished from thymomas because of their malignant histologic features and their different immunohistochemical and genetic features.^{7,43,48} However, thymic carcinomas should be differentiated from primary lung malignancies that metastasize to the thymus and have a similar histologic appearance.^{110,111} Thymic carcinomas often cause pericardial and pleural effusions. The Masaoka staging system can also be used to stage thymic carcinomas.^{35,112,113} It is important to note that thymic carcinomas are very different from thymomas.⁴⁸

Similar to thymomas, patients with completely resected thymic carcinomas have longer survival than those who are either incompletely resected or are unresectable.^{51,53} Thus, management depends on the extent of resection. After resection of thymic carcinomas, postoperative management includes RT with (or without) chemotherapy, depending on the completeness of resection.^{51,52,67} A recent study suggests that adjuvant therapy may not be necessary for early-stage thymic carcinomas.¹¹⁴ For unresectable or metastatic thymic carcinomas, chemotherapy with (or without) RT is recommended.⁹⁷

Unfortunately, thymic carcinomas respond poorly to chemotherapy; carboplatin/paclitaxel is recommended, because it has the highest response rate among thymic carcinomas in clinical trials.^{95,99,115-122} Data suggest that the ADOC (cisplatin, doxorubicin, vincristine, and cyclophosphamide) regimen is also effective, but it is more toxic than carboplatin/paclitaxel.¹²⁰ Data are lacking regarding second-line chemotherapy for thymic carcinomas.⁸⁴ Most of the second-line agents in the NCCN algorithm are appropriate for thymomas.⁸⁵ However, S-1 (an oral fluorouracil) appears to be active in patients with thymic carcinomas.^{123,124} Targeted therapy (eg, sunitinib, sorafenib) may be useful for patients with *c-Kit* mutations; however, these mutations are rare in thymic carcinomas (<10%).^{85,125-129} Patients with thymomas do not have *c-Kit* mutations.¹¹⁰

References

1. Proceedings of the First International Conference on Thymic Malignancies. August 20-21, 2009. Bethesda, Maryland, USA. *J Thorac Oncol* 2010;5:S259-370. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21275152>.
2. Strollo DC, Rosado de Christenson ML, Jett JR. Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. *Chest* 1997;112:511-522. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9266892>.
3. Engels EA, Pfeiffer RM. Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. *Int J Cancer* 2003;105:546-551. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12712448>.
4. Masaoka A. Staging system of thymoma. *J Thorac Oncol* 2010;5:S304-312. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859124>.
5. Kondo K, Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1,320 patients from Japan. *Ann Thorac Surg* 2003;76:878-884; discussion 884-875. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12963221>.
6. Eng TY, Fuller CD, Jagirdar J, et al. Thymic carcinoma: state of the art review. *Int J Radiat Oncol Biol Phys* 2004;59:654-664. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15183468>.
7. Marchevsky A, Marx A, Strobel P, et al. Policies and reporting guidelines for small biopsy specimens of mediastinal masses. *J Thorac Oncol* 2011;6:S1724-1729. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21847054>.
8. Strollo DC, Rosado-de-Christenson ML, Jett JR. Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. *Chest* 1997;112:1344-1357. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9367479>.
9. Rashid OM, Cassano AD, Takabe K. Thymic neoplasm: a rare disease with a complex clinical presentation. *J Thorac Dis* 2013;5:173-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23585946>.
10. Detterbeck FC, Parsons AM. Management of stage I and II thymoma. *Thorac Surg Clin* 2011;21:59-67, vi-vii. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070987>.
11. Detterbeck FC, Zeeshan A. Thymoma: current diagnosis and treatment. *Chin Med J (Engl)* 2013;126:2186-2191. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23769581>.
12. Barth TFE, Leithäuser F, Joos S, et al. Mediastinal (thymic) large B-cell lymphoma: where do we stand? *Lancet Oncol* 2002;3:229-234. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12067685>.
13. Ferolla P, Falchetti A, Filosso P, et al. Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. *J Clin Endocrinol Metab* 2005;90:2603-2609. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15713725>.
14. Teh BT. Thymic carcinoids in multiple endocrine neoplasia type 1. *J Intern Med* 1998;243:501-504. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9681849>.
15. Benveniste MF, Rosado-de-Christenson ML, Sabloff BS, et al. Role of imaging in the diagnosis, staging, and treatment of thymoma. *Radiographics* 2011;31:1847-1861; discussion 1861-1843. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22084174>.
16. Marom EM. Advances in thymoma imaging. *J Thorac Imaging* 2013;28:69-80; quiz 81-63. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23422781>.
17. Marom EM. Imaging thymoma. *J Thorac Oncol* 2010;5:S296-303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859123>.
18. Rosado-de-Christenson ML, Strollo DC, Marom EM. Imaging of thymic epithelial neoplasms. *Hematol Oncol Clin North Am*

2008;22:409-431. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18514124>.

19. Sadohara J, Fujimoto K, Muller NL, et al. Thymic epithelial tumors: comparison of CT and MR imaging findings of low-risk thymomas, high-risk thymomas, and thymic carcinomas. *Eur J Radiol* 2006;60:70-79.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16766154>.

20. Marom EM, Rosado-de-Christenson ML, Bruzzi JF, et al. Standard report terms for chest computed tomography reports of anterior mediastinal masses suspicious for thymoma. *J Thorac Oncol* 2011;6:S1717-1723. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21847053>.

21. Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395-409. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21714641>.

22. Sung YM, Lee KS, Kim BT, et al. 18F-FDG PET/CT of thymic epithelial tumors: usefulness for distinguishing and staging tumor subgroups. *J Nucl Med* 2006;47:1628-1634. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17015898>.

23. Ruffini E, Van Raemdonck D, Detterbeck F, et al. Management of thymic tumors: a survey of current practice among members of the European Society of Thoracic Surgeons. *J Thorac Oncol* 2011;6:614-623. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21266921>.

24. Kondo K. Optimal therapy for thymoma. *J Med Invest* 2008;55:17-28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18319541>.

25. Detterbeck FC, Parsons AM. Thymic tumors. *Ann Thorac Surg* 2004;77:1860-1869. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15111216>.

26. Wright CD. Stage IVA thymoma: patterns of spread and surgical management. *Thorac Surg Clin* 2011;21:93-97, vii. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21070990>.

27. Wright CD. Extended resections for thymic malignancies. *J Thorac Oncol* 2010;5:S344-347. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20859130>.

28. Huang J, Rizk NP, Travis WD, et al. Feasibility of multimodality therapy including extended resections in stage IVA thymoma. *J Thorac Cardiovasc Surg* 2007;134:1477-1483; discussion 1483-1474. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18023668>.

29. Kimura T, Inoue M, Kadota Y, et al. The oncological feasibility and limitations of video-assisted thoracoscopic thymectomy for early-stage thymomas. *Eur J Cardiothorac Surg* 2013. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23761417>.

30. Odaka M, Akiba T, Mori S, et al. Oncological outcomes of thoracoscopic thymectomy for the treatment of stages I-III thymomas. *Interact Cardiovasc Thorac Surg* 2013;17:285-290. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23633558>.

31. Toker A, Sonett J, Zielinski M, et al. Standard terms, definitions, and policies for minimally invasive resection of thymoma. *J Thorac Oncol* 2011;6:S1739-1742. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21847056>.

32. Pennathur A, Qureshi I, Schuchert MJ, et al. Comparison of surgical techniques for early-stage thymoma: feasibility of minimally invasive thymectomy and comparison with open resection. *J Thorac Cardiovasc Surg* 2011;141:694-701. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21255798>.

33. Komanapalli CB, Cohen JI, Sukumar MS. Extended transcervical video-assisted thymectomy. *Thorac Surg Clin* 2010;20:235-243.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20451134>.

34. Limmer KK, Kernstine KH. Minimally invasive and robotic-assisted thymus resection. *Thorac Surg Clin* 2011;21:69-83, vii. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070988>.
35. Detterbeck FC, Nicholson AG, Kondo K, et al. The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. *J Thorac Oncol* 2011;6:S1710-1716. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21847052>.
36. Huang J, Detterbeck FC, Wang Z, Loehrer PJ, Sr. Standard outcome measures for thymic malignancies. *J Thorac Oncol* 2011;6:S1691-1697. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21847049>.
37. Moran CA, Walsh G, Suster S, Kaiser L. Thymomas II: a clinicopathologic correlation of 250 cases with a proposed staging system with emphasis on pathologic assessment. *Am J Clin Pathol* 2012;137:451-461. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22338058>.
38. Kondo K. Tumor-node metastasis staging system for thymic epithelial tumors. *J Thorac Oncol* 2010;5:S352-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859132>.
39. Lee HS, Kim ST, Lee J, et al. A single institutional experience of thymic epithelial tumours over 11 years: clinical features and outcome and implications for future management. *Br J Cancer* 2007;97:22-28. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17592498>.
40. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. *Cancer* 1981;48:2485-2492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7296496>.
41. Wright CD. Management of thymomas. *Crit Rev Oncol Hematol* 2008;65:109-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17570676>.
42. Detterbeck FC. The international thymic malignancy interest group. *J Natl Compr Canc Netw* 2013;11:589-593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23667208>.
43. Travis W, Brambilla E, Muller-Hermelink H, Harris C. Pathology and genetics of tumours of the lung, pleura, thymus and heart. WHO Classification of Tumors, 3rd ed. Lyon: IARC Press; 2004:145-197.
44. Lewis JE, Wick MR, Scheithauer BW, et al. Thymoma. A clinicopathologic review. *Cancer* 1987;60:2727-2743. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3677008>.
45. Park HS, Shin DM, Lee JS, et al. Thymoma. A retrospective study of 87 cases. *Cancer* 1994;73:2491-2498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8174044>.
46. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. *Ann Thorac Surg* 2004;77:1183-1188. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15063231>.
47. Moran CA, Weissferdt A, Kalhor N, et al. Thymomas I: a clinicopathologic correlation of 250 cases with emphasis on the World Health Organization schema. *Am J Clin Pathol* 2012;137:444-450. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22338057>.
48. Marx A, Rieker R, Toker A, et al. Thymic carcinoma: is it a separate entity? From molecular to clinical evidence. *Thorac Surg Clin* 2011;21:25-31 v-vi. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070984>.
49. Margaritora S, Cesario A, Cusumano G, et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery. *Ann Thorac Surg* 2010;89:245-252; discussion 252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20103246>.
50. Regnard JF, Magdeleinat P, Dromer C, et al. Prognostic factors and long-term results after thymoma resection: a series of 307 patients. *J*

Thorac Cardiovasc Surg 1996;112:376-384. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8751506>.

51. Yano M, Sasaki H, Yokoyama T, et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008;3:265-269. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18317069>.

52. Ogawa K, Toita T, Uno T, et al. Treatment and prognosis of thymic carcinoma: a retrospective analysis of 40 cases. Cancer 2002;94:3115-3119. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12115342>.

53. Okereke IC, Kesler KA, Freeman RK, et al. Thymic carcinoma: outcomes after surgical resection. Ann Thorac Surg 2012;93:1668-1672; discussion 1672-1663. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22421590>.

54. Ried M, Potzger T, Sziklavari Z, et al. Extended Surgical Resections of Advanced Thymoma Masaoka Stages III and IVa Facilitate Outcome. Thorac Cardiovasc Surg 2013. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23775415>.

55. Detterbeck F, Youssef S, Ruffini E, Okumura M. A review of prognostic factors in thymic malignancies. J Thorac Oncol 2011;6:S1698-1704. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21847050>.

56. Mehran R, Ghosh R, Maziak D, et al. Surgical treatment of thymoma. Can J Surg 2002;45:25-30. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11837917>.

57. Murakawa T, Nakajima J, Kohno T, et al. Results from surgical treatment for thymoma. 43 years of experience. Jpn J Thorac Cardiovasc Surg 2000;48:89-95. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10769987>.

58. Wakely PE, Jr. Fine needle aspiration in the diagnosis of thymic epithelial neoplasms. Hematol Oncol Clin North Am 2008;22:433-442. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18514125>.

59. Detterbeck FC, Moran C, Huang J, et al. Which way is up? Policies and procedures for surgeons and pathologists regarding resection specimens of thymic malignancy. J Thorac Oncol 2011;6:S1730-1738. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21847055>.

60. Gilhus NE, Owe JF, Hoff JM, et al. Myasthenia gravis: a review of available treatment approaches. Autoimmune Dis 2011;2011:847393. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22007295>.

61. Autoantibodies to acetylcholine receptors in myasthenia gravis. N Engl J Med 1983;308:402-403. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/6823248>.

62. Howard FM, Lennon VA, Finley J, et al. Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis. Ann N Y Acad Sci 1987;505:526-538. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/3479935>.

63. Utsumi T, Shiono H, Kadota Y, et al. Postoperative radiation therapy after complete resection of thymoma has little impact on survival. Cancer 2009;115:5413-5420. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19685527>.

64. Korst RJ, Kansler AL, Christos PJ, Mandal S. Adjuvant radiotherapy for thymic epithelial tumors: a systematic review and meta-analysis. Ann Thorac Surg 2009;87:1641-1647. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19379938>.

65. Forquer JA, Rong N, Fakiris AJ, et al. Postoperative radiotherapy after surgical resection of thymoma: differing roles in localized and regional disease. Int J Radiat Oncol Biol Phys 2010;76:440-445. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19427738>.

66. Ruffini E, Mancuso M, Oliaro A, et al. Recurrence of thymoma: analysis of clinicopathologic features, treatment, and outcome. J Thorac Cardiovasc Surg 1997;113:55-63. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9011702>.

Discussion
updates
program

67. Gomez D, Komaki R, Yu J, et al. Radiation therapy definitions and reporting guidelines for thymic malignancies. *J Thorac Oncol* 2011;6:S1743-1748. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21847057>.
68. Gomez D, Komaki R. Technical advances of radiation therapy for thymic malignancies. *J Thorac Oncol* 2010;5:S336-343. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859129>.
69. Hartford AC, Palisca MG, Eichler TJ, et al. American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology (ACR) Practice Guidelines for Intensity-Modulated Radiation Therapy (IMRT). *Int J Radiat Oncol Biol Phys* 2009;73:9-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19100920>.
70. Moran JM, Dempsey M, Eisbruch A, et al. Safety considerations for IMRT: executive summary. *Med Phys* 2011;38:5067-5072. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21978051>.
71. Gregoire V, Mackie TR. State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83). *Cancer Radiother* 2011;15:555-559. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21802333>.
72. Holmes T, Das R, Low D, et al. American Society of Radiation Oncology recommendations for documenting intensity-modulated radiation therapy treatments. *Int J Radiat Oncol Biol Phys* 2009;74:1311-1318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19616738>.
73. ICRU Report 83: Prescribing, Recording, and Reporting Intensity Modulated Photon Beam Therapy (IMRT). *Journal of the ICRU* 2010;10. Available at: <http://jicru.oxfordjournals.org/content/10/1.toc>.
74. Kong FM, Pan C, Eisbruch A, Ten Haken RK. Physical models and simpler dosimetric descriptors of radiation late toxicity. *Semin Radiat Oncol* 2007;17:108-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17395041>.
75. Milano MT, Constine LS, Okunieff P. Normal tissue tolerance dose metrics for radiation therapy of major organs. *Semin Radiat Oncol* 2007;17:131-140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17395043>.
76. Myojin M, Choi NC, Wright CD, et al. Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study. *Int J Radiat Oncol Biol Phys* 2000;46:927-933. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10705015>.
77. Mornex F, Resbeut M, Richaud P, et al. Radiotherapy and chemotherapy for invasive thymomas: a multicentric retrospective review of 90 cases. The FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. *Int J Radiat Oncol Biol Phys* 1995;32:651-659. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7790251>.
78. Singhal S, Shrager JB, Rosenthal DI, et al. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. *Ann Thorac Surg* 2003;76:1635-1641; discussion 1641-1632. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14602300>.
79. Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? *Eur J Cardiothorac Surg* 2007;31:109-113. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17110124>.
80. Mangi AA, Wright CD, Allan JS, et al. Adjuvant radiation therapy for stage II thymoma. *Ann Thorac Surg* 2002;74:1033-1037. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12400741>.
81. Sugie C, Shibamoto Y, Ikeya-Hashizume C, et al. Invasive thymoma: postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination. *J Thorac Oncol* 2008;3:75-81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18166844>.

82. Ogawa K, Uno T, Toita T, et al. Postoperative radiotherapy for patients with completely resected thymoma: a multi-institutional, retrospective review of 103 patients. *Cancer* 2002;94:1405-1413. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11920495>.
83. Cowen D, Richaud P, Mornex F, et al. Thymoma: results of a multicentric retrospective series of 149 non-metastatic irradiated patients and review of the literature. FNCLCC trialists. Federation Nationale des Centres de Lutte Contre le Cancer. *Radiother Oncol* 1995;34:9-16. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7792406>.
84. Girard N, Lal R, Wakelee H, et al. Chemotherapy definitions and policies for thymic malignancies. *J Thorac Oncol* 2011;6:S1749-1755. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21847058>.
85. Girard N. Chemotherapy and targeted agents for thymic malignancies. *Expert Rev Anticancer Ther* 2012;12:685-695. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22594902>.
86. Loehrer PJ, Sr., Chen M, Kim K, et al. Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. *J Clin Oncol* 1997;15:3093-3099. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9294472>.
87. Loehrer PJ, Kim K, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. *J Clin Oncol* 1994;12:1164-1168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8201378>.
88. Giaccone G, Ardizzoni A, Kirkpatrick A, et al. Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. *J Clin Oncol* 1996;14:814-820. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8622029>.
89. Shin DM, Walsh GL, Komaki R, et al. A multidisciplinary approach to therapy for unresectable malignant thymoma. *Ann Intern Med* 1998;129:100-104. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9669967>.
90. Fornasiero A, Daniele O, Ghiotto C, et al. Chemotherapy for invasive thymoma. A 13-year experience. *Cancer* 1991;68:30-33. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2049749>.
91. Loehrer PJ, Jiroutek M, Aisner S, et al. Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. *Cancer* 2001;91:2010-2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11391579>.
92. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. *Lung Cancer* 2004;44:369-379. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15140551>.
93. Lucchi M, Melfi F, Dini P, et al. Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. *J Thorac Oncol* 2006;1:308-313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17409875>.
94. Yokoi K, Matsuguma H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. *J Thorac Oncol* 2007;2:73-78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17410014>.
95. Lemma GL, Loehrer PJ, Sr., Lee JW, et al. A phase II study of carboplatin plus paclitaxel in advanced thymoma or thymic carcinoma: E1C99 [abstract]. *J Clin Oncol* 2008;26(Suppl 15):Abstract 8018. Available at: http://meeting.ascopubs.org/cgi/content/abstract/26/15_suppl/8018.

96. Venuta F, Rendina EA, Longo F, et al. Long-term outcome after multimodality treatment for stage III thymic tumors. *Ann Thorac Surg* 2003;76:1866-1872; discussion 1872. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14667602>.
97. Rajan A, Giaccone G. Chemotherapy for thymic tumors: induction, consolidation, palliation. *Thorac Surg Clin* 2011;21:107-114, viii. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070992>.
98. Schmitt J, Loehrer PJ, Sr. The role of chemotherapy in advanced thymoma. *J Thorac Oncol* 2010;5:S357-360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859133>.
99. Lemma GL, Lee JW, Aisner SC, et al. Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. *J Clin Oncol* 2011;29:2060-2065. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21502559>.
100. Furugen M, Sekine I, Tsuta K, et al. Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. *Jpn J Clin Oncol* 2011;41:1013-1016. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21742653>.
101. Riely GJ, Huang J. Induction therapy for locally advanced thymoma. *J Thorac Oncol* 2010;5:S323-326. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859127>.
102. Wright CD, Choi NC, Wain JC, et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. *Ann Thorac Surg* 2008;85:385-389. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18222230>.
103. Longo F, De Filippis L, Zivi A, et al. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial. *Am J Clin Oncol* 2012;35:105-109. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21325939>.
104. Loehrer PJ, Sr., Wang W, Johnson DH, et al. Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. *J Clin Oncol* 2004;22:293-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14722038>.
105. Palmieri G, Merola G, Federico P, et al. Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs). *Ann Oncol* 2010;21:1168-1172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19880439>.
106. Highley MS, Underhill CR, Parnis FX, et al. Treatment of invasive thymoma with single-agent ifosfamide. *J Clin Oncol* 1999;17:2737-2744. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10561348>.
107. Pan CC, Chen PC, Wang LS, et al. Thymoma is associated with an increased risk of second malignancy. *Cancer* 2001;92:2406-2411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11745297>.
108. Suster S, Rosai J. Thymic carcinoma. A clinicopathologic study of 60 cases. *Cancer* 1991;67:1025-1032. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1991250>.
109. Huang J, Rizk NP, Travis WD, et al. Comparison of patterns of relapse in thymic carcinoma and thymoma. *J Thorac Cardiovasc Surg* 2009;138:26-31. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19577051>.
110. Strobel P, Hohenberger P, Marx A. Thymoma and thymic carcinoma: molecular pathology and targeted therapy. *J Thorac Oncol* 2010;5:S286-290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20859121>.
111. Moran CA, Suster S. Thymic carcinoma: current concepts and histologic features. *Hematol Oncol Clin North Am* 2008;22:393-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18514123>.

112. Hosaka Y, Tsuchida M, Toyabe S, et al. Masaoka stage and histologic grade predict prognosis in patients with thymic carcinoma. *Ann Thorac Surg* 2010;89:912-917. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20172153>.

113. Blumberg D, Burt ME, Bains MS, et al. Thymic carcinoma: current staging does not predict prognosis. *J Thorac Cardiovasc Surg* 1998;115:303-308; discussion 308-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9475524>.

114. Sakai M, Onuki T, Inagaki M, et al. Early-stage thymic carcinoma: is adjuvant therapy required? *J Thorac Dis* 2013;5:161-164. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23585943>.

115. Maruyama R, Suemitsu R, Okamoto T, et al. Persistent and aggressive treatment for thymic carcinoma. Results of a single-institute experience with 25 patients. *Oncology* 2006;70:325-329. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17164588>.

116. Weide LG, Ulbright TM, Loehrer PJ, Williams SD. Thymic carcinoma. A distinct clinical entity responsive to chemotherapy. *Cancer* 1993;71:1219-1223. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8435796>.

117. Lucchi M, Mussi A, Ambroggi M, et al. Thymic carcinoma: a report of 13 cases. *Eur J Surg Oncol* 2001;27:636-640. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11669591>.

118. Yoh K, Goto K, Ishii G-i, et al. Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. *Cancer* 2003;98:926-931. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12942558>.

119. Igawa S, Murakami H, Takahashi T, et al. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. *Lung Cancer* 2010;67:194-197. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19409644>.

120. Koizumi T, Takabayashi Y, Yamagishi S, et al. Chemotherapy for advanced thymic carcinoma: clinical response to cisplatin, doxorubicin, vincristine, and cyclophosphamide (ADOC chemotherapy). *Am J Clin Oncol* 2002;25:266-268. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12040285>.

121. Kanda S, Koizumi T, Komatsu Y, et al. Second-line chemotherapy of platinum compound plus CPT-11 following ADOC chemotherapy in advanced thymic carcinoma: analysis of seven cases. *Anticancer Res* 2007;27:3005-3008. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17695487>.

122. Komatsu Y, Koizumi T, Tanabe T, et al. Salvage chemotherapy with carboplatin and paclitaxel for cisplatin-resistant thymic carcinoma--three cases. *Anticancer Res* 2006;26:4851-4855. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17214351>.

123. Okuma Y, Shimokawa T, Takagi Y, et al. S-1 is an active anticancer agent for advanced thymic carcinoma. *Lung Cancer* 2010;70:357-363. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20951466>.

124. Koizumi T, Agatsuma T, Komatsu Y, Kubo K. Successful S-1 monotherapy for chemorefractory thymic carcinoma. *Anticancer Res* 2011;31:299-301. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21273614>.

125. Kelly RJ, Petrini I, Rajan A, et al. Thymic malignancies: from clinical management to targeted therapies. *J Clin Oncol* 2011;29:4820-4827. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22105817>.

126. Strobel P, Bargou R, Wolff A, et al. Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. *Br J Cancer* 2010;103:196-200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20571495>.

127. Bisagni G, Rossi G, Cavazza A, et al. Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated

metastatic thymic carcinoma. J Thorac Oncol 2009;4:773-775. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19461405>.

128. Strobel P, Hartmann M, Jakob A, et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. N Engl J Med 2004;350:2625-2626. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15201427>.

129. Girard N. Targeted therapies for thymic malignancies. Thorac Surg Clin 2011;21:115-123, viii. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21070993>.



Discussion
update in
progress